Brain Cancer section

Brain Cancer News and Features

Certain nutrients may fuel cancer therapy resistance

Certain nutrients may fuel cancer therapy resistance

Tumors can leverage glucose and acetate to resist targeted therapies directed at specific cellular molecules.

Low-grade brain tumor diagnosis redefined

A tumor's DNA composition plays a key role in whether a glioma may transform into a more serious glioblastoma.

Survival in adult patients with low-grade brain tumors has improved

Survival in adult patients with low-grade brain tumors has improved

Outcomes for patients with low-grade gliomas have improved significantly in recent years, according to an analysis of clinical data collected from a US cancer registry over the past decade.

Drug treatment may benefit only select group of patients with glioblastoma

Drug treatment may benefit only select group of patients with glioblastoma

Clinicians testing dasatinib, approved for several blood cancers, were hoping to find that it would slow the growth of glioblastomas.

Identifying mutations in relapsed pediatric neuroblastoma may lead to better treatment options

Identifying mutations in relapsed pediatric neuroblastoma may lead to better treatment options

Majority of pediatric patients with relapsed neuroblastoma studied harbored mutations that promoted RAS-MAPK pathway signaling.

Brain Cancer Videos

Brain Cancer Clinical Trials

Certain nutrients may fuel cancer therapy resistance

Tumors can leverage glucose and acetate to resist targeted therapies directed at specific cellular molecules.

Low-grade brain tumor diagnosis redefined

A tumor's DNA composition plays a key role in whether a glioma may transform into a more serious glioblastoma.

Survival in adult patients with low-grade brain tumors has improved

Outcomes for patients with low-grade gliomas have improved significantly in recent years, according to an analysis of clinical data collected from a US cancer registry over the past decade.

Drug treatment may benefit only select group of patients with glioblastoma

Clinicians testing dasatinib, approved for several blood cancers, were hoping to find that it would slow the growth of glioblastomas.

Identifying mutations in relapsed pediatric neuroblastoma may lead to better treatment options

Majority of pediatric patients with relapsed neuroblastoma studied harbored mutations that promoted RAS-MAPK pathway signaling.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs